Chemoprevention for women at risk for breast cancer has been shown to be effective, but in actual practice, women's uptake of chemoprevention has been poor. We explored factors that influence acceptability, adherence, and dropout in the International Breast (Prevention) Intervention Study during our first 3 years of activity at the Modena Familial Breast and Ovarian Cancer Center. We evaluated socio-demographic characteristics, health status, adherence, and side effect intensity. Semi-structured interviews analyzed reasons for accepting/refusing/stopping the trial. A total of 471 postmenopausal women were invited to participate, of which 319 declined to participate (68%), 137 accepted to participate (29%), and 15 participants did not make a...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...
The aim of this study was the identification of subgroups of patients at higher risk of nonadherence...
BACKGROUND: : Women at increased risk of breast cancer (BC) are not widely accepting of chemoprevent...
Chemoprevention for women at risk for breast cancer has been shown to be effective, but in actual pr...
There is significant interest in developing chemoprevention trials for women at high risk for breast...
Background: The effectiveness of preventive therapy for breast cancer depends on adequate uptake, bu...
Introduction: Tamoxifen and raloxifene are chemopreventive drugs that can reduce women's relative ri...
SGS is supported by a Cancer Research UK Postdoctoral Fellowship (C42785/A17965). AF is supported by...
Introduction: Uptake of preventive therapies for breast cancer is low. We examined whether women at ...
Objective: The purpose of this study was to test the effect of patient involvement levels, developed...
Background Breast cancer chemoprevention can reduce breast cancer incidence in high-risk women; howe...
Women at increased breast cancer (BC) risk are eligible for chemoprevention. Healthy lifestyles are ...
Abstract Introduction Tamoxifen and raloxifene are ch...
Few studies have explored factors related to participation in cancer chemoprevention trials. The pur...
Background: Chemoprevention for women at elevated risk of breast cancer is endorsed by international...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...
The aim of this study was the identification of subgroups of patients at higher risk of nonadherence...
BACKGROUND: : Women at increased risk of breast cancer (BC) are not widely accepting of chemoprevent...
Chemoprevention for women at risk for breast cancer has been shown to be effective, but in actual pr...
There is significant interest in developing chemoprevention trials for women at high risk for breast...
Background: The effectiveness of preventive therapy for breast cancer depends on adequate uptake, bu...
Introduction: Tamoxifen and raloxifene are chemopreventive drugs that can reduce women's relative ri...
SGS is supported by a Cancer Research UK Postdoctoral Fellowship (C42785/A17965). AF is supported by...
Introduction: Uptake of preventive therapies for breast cancer is low. We examined whether women at ...
Objective: The purpose of this study was to test the effect of patient involvement levels, developed...
Background Breast cancer chemoprevention can reduce breast cancer incidence in high-risk women; howe...
Women at increased breast cancer (BC) risk are eligible for chemoprevention. Healthy lifestyles are ...
Abstract Introduction Tamoxifen and raloxifene are ch...
Few studies have explored factors related to participation in cancer chemoprevention trials. The pur...
Background: Chemoprevention for women at elevated risk of breast cancer is endorsed by international...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...
The aim of this study was the identification of subgroups of patients at higher risk of nonadherence...
BACKGROUND: : Women at increased risk of breast cancer (BC) are not widely accepting of chemoprevent...